
-
4D Molecular Therapeutics NasdaqGS:FDMT 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
Location: 5858 Horton Street, Emeryville, CA, 94608, United States | Website: https://www.4dmoleculartherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-125.7M
Cash
321.4M
Avg Qtr Burn
-38.31M
Short % of Float
13.19%
Insider Ownership
3.88%
Institutional Own.
95.90%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
4D-150 Details Wet age-related macular degeneration | Phase 2b Data readout | |
4D-150 Details Diabetic macular edema | Phase 2 Data readout | |
4D-310 Details Fabry disease | Phase 1/2 Data readout | |
4D-710 Details Cystic fibrosis | Phase 1/2 Data readout | |
4D-175 Details Geographic atrophy | Phase 1 Update | |
4D-125 Details X-linked retinitis pigmentosa | Failed Discontinued | |
4D-110 Details Choroideremia | Failed Discontinued |